Ernexa Therapeutics Inc.
Developing targeted, off-the-shelf cell therapies for cancer and autoimmune diseases.
ERNA | NDAQ
Overview
Corporate Details
- ISIN(s):
- US6294106066 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 1035 CAMBRIDGE STREET, 2141 CAMBRIDGE
- Website:
- https://www.ernexatx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Ernexa Therapeutics Inc. is a preclinical-stage biotechnology company developing innovative cell therapies for advanced cancer and autoimmune diseases. The company's core technology platform engineers induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs). These engineered iMSCs leverage their natural ability to home to sites of tumors and inflammation, serving as a targeted delivery vehicle for therapeutic cytokines. This approach enables the development of scalable, allogeneic ("off-the-shelf") treatments. The company's pipeline includes ERNA-101, a lead candidate for ovarian cancer, and ERNA-201 for autoimmune disorders.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Ernexa Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Ernexa Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Ernexa Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
